[The value of pharmaco-economics: the point of view of the drug industry].
This article describes the causes of the progressive increase of health costs and some of the methods used to contain them. The author addresses the question of assessment of efficacy, both in the area of diagnosis and treatment: what is its definition; which studies are currently under way to improve it; how is it measured today; what are its limitations; which fears does all this generate? The author finally points to the need of avoiding to restrain from an approach strictly limited to pharmaco-economics: the more global problem of health economics is much wider.
Glaxo Wellcome Belgium SA.
A
A
De Wever
D003362:Cost-Benefit Analysis; D003469:Culture; D003933:Diagnosis; D016527:Drug Costs; D004345:Drug Industry; D017850:Economics, Pharmaceutical; D005060:Europe; D017048:Health Care Costs; D019981:Health Care Sector; D006801:Humans; D008329:Managed Care Programs / Q000191:economics; D010043:Outcome and Process Assessment, Health Care; D011057:Politics; D013812:Therapeutics / Q000191:economics; D014481:United States